Company: PTHS
Filing Date: 2025-05-27
Form Type: DEFM14C
Source: 0001140361-25-020509
Chunk: 534

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-27
Form: DEFM14C
Chunk 534
---
 Loan Payable                  |     | Outstanding 
   Principal |     |   Unamortized 
 Debt Discount |     |       Outstanding 
 Principal, net of 
     Debt Discount |
| Investor Note                 |     |    $205,008 |     |        -2,729 |     |          $202,279 |
| Total as of December 31, 2023 |     |    $205,008 |     |      $(2,729) |     |          $202,279 |

| Investor Loan                 |     | Outstanding 
   Principal |     |   Unamortized 
 Debt Discount |     |       Outstanding 
 Principal, net of 
     Debt Discount |
| Investor Note                 |     |    $450,000 |     |      -133,676 |     |          $316,324 |
| Total as of December 31, 2023 |     |    $450,000 |     |    $(133,676) |     |          $316,324 |

NOTE 6 - STOCKHOLDERS’ EQUITY Initial Public Offering On February 21, 2024, the Company completed its IPO and issued 1,100,000 shares of Common Stock at a price of $6.00 per share. The aggregate net proceeds from the IPO were approximately $5.9 million after deducting approximately $0.9 million of underwriting discounts and commissions and offering expenses. Stock Split On February 15, 2024, the Company effected a 9-for-1 reverse stock split. All share and per share amounts have been retrospectively adjusted for the reverse stock split. 2023 Plan Amendment On June 12, 2024, the Board authorized an amendment to the Chromocell Therapeutics Corporation 2023 Equity Incentive Plan (the “2023 Plan”) to increase the number of shares of Common Stock authorized for issuance thereunder by 1,500,000 from 444,444 shares to 1,944,444 shares. On October 22, 2024, the 2023 Plan Amendment was approved by the affirmative vote of a majority of the outstanding shares of Common Stock present in person, by remote communication, if applicable, or represented by proxy at the Annual Meeting. Share Forfeiture Pursuant to the terms of the April Bridge Financing, Chromocell Holdings forfeited 133,745 of the shares of Common Stock of the Company on April 17, 2023. All shareholders with ownership stakes greater than